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 Letter to the Editor 
 Neuroimaging research has shown that ADs can diminish the 
neural processing of both rewarding and aversive stimuli in healthy 
controls when investigating the placebo-controlled effect  [6] . This 
could account for the experience of emotional blunting described 
by some patients during selective serotonin reuptake inhibitor 
treatment  [7] . Hence it seems that some ADs can suppress the 
brain system that is important for the generation of positive emo-
tions (reward system) in addition to the one generating negative 
emotions (stress system). It was therefore hypothesized that AD 
and MBCT have a synergistic effect on NA but that AD inhibits the 
positive effect of MBCT on PA.
 In the trial, individuals (n = 129) with residual depressive symp-
toms (score  ≥ 7 on the 17-item Hamilton Depression Rating Scale 
after at least 1 prior episode of MDD) were randomized to either 
MBCT or WLCG [for details on the procedures, see  4 ]. One of the 
exclusion criteria for participation was recent (in the past 4 weeks) 
or upcoming changes in ongoing psychological or pharmacological 
treatment. PA (mean of items: I feel ‘happy’, ‘satisfied’, ‘strong’, en-
thusiastic’, ‘curious’, cheerful’ and ‘inspired’) and NA (mean of 
items: I feel ‘down’, ‘anxious’, ‘lonely’, ‘suspicious’, ‘disappointed’, 
‘insecure’ and ‘guilty’) were assessed using experience sampling 
methodology before and after the treatment (or waiting list) period. 
Analyses were executed with the XTMIXED command when they 
concerned multilevel data and LOGIT and REGRESS commands 
for, respectively, dichotomous and quantitative unilevel data in 
STATA 12.1.
 Since AD use was not randomized within treatment groups, 
potential confounder variables were examined. It was investigated 
whether (a) treatment groups (MBCT and WLCG) differed in their 
AD use, and (b) participants taking ADs (AD+) differed from par-
ticipants not taking ADs (AD–) with regard to the outcome mea-
sures at baseline (PA, NA) or potential confounding variables ( ta-
ble 1 ) both overall as well as within treatment groups (MBCT and 
WLCG). Based on these analyses only antipsychotic use was found 
to be a potential confounder.
 Significant three-way interaction [MBCT/WLCG × time (pre/
post) × AD (yes/no)] effects were found for both NA (b = –0.208, 
p = 0.001)  and PA (b = –0.171, p = 0.031) and these effects re-
mained significant after controlling for the interaction of anti-
psychotic use with time and group (NA: b = –0.207, p = 0.002; PA: 
b = –0.187, p = 0.023).
 NA: When stratifying the analysis by use of ADs (i.e., two-way 
interaction: MBCT/WLCG × time), the impact of MBCT (com-
pared to WLCG) on decrease in NA was stronger in AD+ (b = 
–0.424, p < 0.001) than in AD– (b = –0.216, p < 0.001). The results 
of the three-way interaction analysis (see above) indicated that this 
difference was statistically significant. PA: When stratifying the 
 Antidepressant medication (AD) is the most often used treat-
ment for major depressive disorder (MDD), prescribed to an es-
timated 73.8% of the MDD patients in care in 2007  [1] . However, 
many patients with MDD who experience full symptomatic re-
mission after AD treatment still have residual depressive symp-
toms, which have been associated with continued impaired func-
tioning  [2] . The sequential addition of psychotherapy to pharma-
cotherapy has therefore been considered, and shown, to offer a 
better possibility of improving long-term outcome in terms of 
 reduced relapse/recurrence  [3] . Since positive emotions play a 
crucial role in the development of long-term personal skills and 
resources through broadening awareness and behavioural rep-
ertoires  [4] , it is of interest to examine whether adding psycho-
therapy to AD treatment has beneficial effects on positive emo-
tional experiences.
 We explored this question in a randomized controlled trial of 
mindfulness-based cognitive therapy (MBCT) versus a waiting list 
control group (WLCG), based upon which it was previously shown 
that MBCT increases positive affect (PA) in people with residual 
depressive symptoms  [5] . Participants in this randomized con-
trolled trial were asked to continue any pharmacological treatment 
during participation in the study, hence providing us with a sub-
group of people taking ADs. It was investigated whether this sub-
group responded differently to MBCT treatment in terms of both 
PA and negative affect (NA).
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analysis by use of ADs, the impact of MBCT (compared to WLCG) 
on increase in PA was stronger in AD– (b = 0.543, p < 0.001) than 
in AD+ (b = 0.372, p < 0.001). The results of the three-way interac-
tion analysis (see above) indicated that this difference was statisti-
cally significant.
 The hypothesis concerning NA was therefore confirmed: 
MBCT with subjects taking AD (MBCT AD+ ) decreases NA more 
than only AD in combination with WLCG (WLCG AD+ ), indicating 
a beneficial effect of sequentially adding psychotherapy to AD. Ad-
ditionally, the MBCT AD+ group showed a larger decrease in NA 
compared to people receiving MBCT while not taking AD (MBC-
T AD– ). Hence it appears that AD and MBCT treatment have a syn-
ergistic effect in decreasing daily life negative emotions.
 With regard to PA the hypothesis was additionally confirmed. 
Adding MBCT to AD (MBCT AD+ ) increased PA more than just 
AD in combination with WLCG (WLCG  AD+ ), again indicating a 
beneficial effect of sequentially adding psychotherapy to AD. 
However, the MBCT AD+ group showed a  smaller increase in PA 
compared to people receiving MBCT while  not receiving AD 
(MBCT AD– ). These results are in line with the neuroimaging re-
search showing that ADs seem to dampen the brain reward system 
responsible for the experience of these emotions  [6] .
 In summary, sequentially adding psychotherapy to AD in the 
treatment of residual depressive symptoms seems beneficial in 
that it both decreases NA and increases PA. However, in terms 
of PA, the group that showed the largest increase were the par-
ticipants  without  AD who received MBCT treatment. Since the 
generation of positive emotions is crucial in the initiation of a 
positive spiral towards recovery  [4] , long-term outcomes of this 
contingent inhibiting effect of AD on psychotherapy outcome in 
terms of PA will have to be investigated in more detail in exper-
imental set-ups. If our findings are replicated it would implicate 
that the sequential addition of psychotherapy to AD could be 
less efficient than discontinuing AD before/during receiving 
psychotherapy especially for improving long-term outcomes.
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 Table 1.  Characteristics of treatment group combinations
MBCT WLCG
AD– AD+ AD– AD+
Patients, n 42 21 41 25
NA (baseline) 2.0 ± 1.1 2.1 ± 1.1 2.1 ± 1.1 1.9 ± 1.0
PA (baseline) 3.6 ± 1.3 3.6 ± 1.3 3.7 ± 1.2 3.9 ± 1.2
Male gender, % 24 14 32 20
Age, years 44.3 ± 9.8 44.5 ± 9.8 41.9 ± 9.9 45.4 ± 8.6
Previous depressive episodes (3 or more), % 40 55 39 52
YTQ total score 43.8 ± 13.7 45.8 ± 15.3 46.3 ± 17.1 43.6 ± 15.3
HDRS total score at baseline 10.6 ± 3.7 10.0 ± 3.2 10.4 ± 3.3 9.9 ± 4.0
Total minutes practiced during MBCT 1,526 ± 621 1,310 ± 699
Taking anxiolytic medication, % 17 24 10 20
Taking antipsychotic medication, % 0 19 2 4
Psychotherapy, % 19 29 18 8
Counselling, % 7 24 5 24
SSRI, n 14 20
TCA, n 4 0
SNRI, n 1 0
MAOI, n 0 1
SARI, n 1 1
NaSSA, n 0 2
NaSSA and SDRI, n 1 0
SARI and SNRI, n 0 1
 Values represent number, mean ± SD or percentage. YTQ = Youth Trauma Questionnaire; HDRS = Hamil-
ton Depression Rating Scale; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; 
SNRI = serotonin and norepinephrine reuptake inhibitor; MAOI = monoamine oxidase inhibitor; SARI = se-
rotonin antagonist and reuptake inhibitor; NaSSA = noradrenergic and specific serotonergic antidepressant; 
SDRI = serotonin-dopamine reuptake inhibitor.
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